Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland

Launched by UNIVERSITY OF BASEL · Apr 18, 2017

Keywords

ClinConnect Summary

The CASCADE study is a clinical trial focused on understanding how to better identify and support family members of individuals with hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) in Switzerland. The goal is to improve the use of genetic testing, which can help detect cancer risks early and provide options for better care and prevention. The study will involve talking to patients already diagnosed with HBOC or LS and their relatives to learn about their experiences, needs for medical care, and how well they communicate about these health issues within their families.

To be eligible for this study, participants must be at least 18 years old, live in Switzerland, and be carriers of specific genetic mutations linked to HBOC or LS. They should also have at least one living blood relative. Participants can expect to complete surveys that ask about their health, family history, and thoughts on genetic services. Through this research, the study aims to enhance understanding and access to genetic testing, ultimately leading to better health outcomes for families affected by these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Carrier of a mutation associated with HBOC or LS
• • 2. Have at least one living blood relative
• • 3. Men and women
• • 4. 18 years old and older
• • 5. Mentally and physically able to provide informed consent
• • 6. Can read and speak German or French or Italian or English
• • 7. Currently living in Switzerland.
• Exclusion Criteria:
• • 1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes
• • 2. Not living in Switzerland
• • 3. Patients who are critically ill and cannot complete the CASCADE survey
• • 4. Participants who are institutionalized (e.g., nursing homes) or incarcerated